Vericel Corporation develops and markets advanced therapies for sports medicine and severe burn care, with U.S. commercial products that include MACI, Epicel and NexoBrid. News about VCEL commonly covers financial results, MACI procedure and surgeon activity, burn care revenue trends, and manufacturing capacity for cell therapy products.
Company updates also include regulatory and operational milestones, such as FDA approval of commercial MACI manufacturing at Vericel's advanced therapy facility, as well as BARDA-supported procurement and development activities for NexoBrid. The recurring themes center on commercialization, specialty biologics supply, product access and development within Vericel's cellular therapy portfolio.
Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present at the Canaccord Genuity Musculoskeletal Conference on March 7, 2023, at 12:30 p.m. ET. A webcast of this presentation can be accessed through Vericel's Investor Relations website. The company specializes in advanced therapies for sports medicine and severe burn care, offering products like MACI®, an autologous scaffold for knee cartilage defects, and Epicel®, a permanent skin replacement for severe burns. Vericel also holds exclusive rights to NexoBrid® for burn treatment. For further details, visit the company's official website.
Vericel Corporation (NASDAQ:VCEL) reported robust financial results for Q4 and full-year 2022, with total revenue reaching $52.7 million in Q4, a 31% increase in net income, and total annual revenue of $164.4 million. MACI revenue contributed $132 million for 2022, showing a 24% year-over-year growth in Q4. The company anticipates 2023 total revenue between $180 million and $188 million with MACI revenue estimated at $152 million to $156 million. Notably, Vericel achieved FDA approval for NexoBrid, paving the way for further growth.
Vericel Corporation (NASDAQ: VCEL) is set to report its fourth-quarter 2022 financial results on February 23, 2023. Management will host a conference call and webcast at 8:30 a.m. (ET) to discuss these results along with important business highlights. Interested participants can access the live webcast on Vericel's Investor Relations page and register for the call via the provided link to receive dial-in details. A replay will be available on their website until February 23, 2024. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing notable products like MACI® and Epicel®.
Vericel Corporation (NASDAQ:VCEL) reported preliminary financial results for 2022, with total revenue expected between $164 to $165 million. MACI revenue is expected at around $132 million, while Burn Care revenue approximates $32.5 million. Notably, MACI revenue is anticipated to grow by 24% in Q4 compared to the previous year. The company plans to accelerate the launch of MACI’s arthroscopic delivery to 2024 and expects positive adjusted EBITDA for the tenth consecutive quarter. As of year-end 2022, Vericel had around $140 million in cash, with no debt.
Kytopen, a biotechnology firm, has appointed Dr. Paul K. Wotton as the new Chair of its Board of Directors. With 35 years of experience in the biopharmaceutical industry, Dr. Wotton aims to enhance Kytopen's strategic growth by leveraging its innovative non-viral delivery technology for gene-modified cell therapies. Kytopen, co-founded by Dr. Paulo Garcia, focuses on making the process of cell therapy discovery more efficient and accessible. This leadership change is poised to align with the company’s mission to improve patient access to advanced living medicines.
Vericel Corporation (NASDAQ:VCEL) announced that President and CEO Nick Colangelo will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 10:30 a.m. ET. The presentation will focus on the company's advancements in sports medicine and severe burn care. A webcast will be available on the Investor Relations section of the Vericel website. Vericel is known for its cell therapy products, including MACI® and Epicel®, addressing cartilage defects and severe burns, respectively.
Vericel Corporation (NASDAQ:VCEL) has announced FDA approval for NexoBrid (anacaulase-bcdb), aimed at non-surgical eschar removal in adults with deep partial- and full-thickness thermal burns. The approval stems from the pivotal Phase 3 DETECT trial, which revealed a significantly higher rate of complete eschar removal compared to placebo, alongside reduced surgical intervention rates. NexoBrid is expected to launch commercially in the U.S. by Q2 2023, promising to address the unmet needs in burn care and potentially establishing itself as the new standard for treatment.
Vericel Corporation (NASDAQ:VCEL) announced its leadership's participation in two upcoming conferences. Nick Colangelo, President and CEO, will present at the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum on November 17, 2022, at 10:00 a.m. ET. Joe Mara, CFO, will follow at the Stephens Annual Investment Conference at 11:00 a.m. ET on the same day. Webcasts of the presentations will be available on Vericel's Investor Relations website. The company specializes in advanced therapies for sports medicine and severe burn care.
Vericel Corporation (NASDAQ:VCEL) reported third-quarter 2022 net product revenue of $38.6 million, an increase of 12% year-over-year. MACI net revenue rose by 30% to $31.0 million, while Epicel revenue was $7.3 million. Gross margin stood at 65%, but the company incurred a net loss of $6.6 million or $0.14 per share. Non-GAAP adjusted EBITDA was $3.3 million. The company expects full-year revenue of $164 to $166 million with MACI revenue projected at $130 to $132 million.
Vericel Corporation (NASDAQ:VCEL) will report its third-quarter 2022 financial results on November 9, 2022. The company specializes in advanced therapies for sports medicine and severe burn care, marketing two prominent cell therapy products: MACI and Epicel. A conference call will be held at 8:30 a.m. ET to discuss the results and key business highlights. Interested parties can join via a live webcast on the company's Investor Relations website. Presentation slides will also be available during the call.